United Therapeutics (UTHR) Amortization of Deferred Charges (2009 - 2016)

United Therapeutics has disclosed Amortization of Deferred Charges across 8 years of filings, most recently posting $100000.0 for Q1 2016.

• Amortization of Deferred Charges for Q1 2016 came in at $100000.0, down 95.0% year-over-year; the trailing twelve-month figure through Jun 2016 was $941000.0 (down 91.46% YoY), and the FY2015 annual result was $5.9 million, down 52.3% from the prior year.
• Amortization of Deferred Charges came in at $100000.0 for Q1 2016 at United Therapeutics, down from $433000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $3.4 million in Q3 2014 to a low of $100000.0 in Q1 2016.
• The 5-year median for Amortization of Deferred Charges is $3.0 million (2012), against an average of $2.5 million.
• Across the five-year window, Amortization of Deferred Charges soared 47.5% in 2013 and sank 95.0% in 2016, its largest moves.
• United Therapeutics' Amortization of Deferred Charges stood at $2.2 million in 2012, then jumped by 47.5% to $3.2 million in 2013, then declined by 21.98% to $2.5 million in 2014, then slumped by 82.6% to $433000.0 in 2015, then slumped by 76.91% to $100000.0 in 2016.
• The last three Amortization of Deferred Charges figures came in at $100000.0 (Q1 2016), $433000.0 (Q4 2015), and $408000.0 (Q3 2015), per Business Quant data.